VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B | MicrobiomeTrials← Back to trialsNCT06092333
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-01-31Est. Completion: 2028-02-29
Enrollment target: 50 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Chronic Hepatitis B Infection
France is a low-endemicity country for hepatitis B virus (HBV) infection. In 2016, the prevalence of chronic HBV infecti…
Créteil, FranceEst. completion Sep 1, 2029
Lymphoma
Background:
People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or …
Bethesda, United StatesEst. completion Nov 15, 2036